Stay updated on Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Sign up to get notified when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.

Latest updates to the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page
- Check2 days agoChange DetectedMinor revision label updated from v3.3.3 to v3.3.4; no changes to study details, eligibility criteria, or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedA new consolidated Locations section lists participating sites by state (Florida, Missouri, Oklahoma, Tennessee, Texas, Wisconsin) and the prior state-specific location subsections have been removed.SummaryDifference0.7%

- Check53 days agoChange DetectedRevision updated to v3.3.2. The previous revision v3.2.0 was removed.SummaryDifference0.1%

- Check60 days agoChange DetectedRemoved a general government funding and operating status notice from the page, which previously informed users that information may not be up to date and that the NIH Clinical Center is open. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check74 days agoChange DetectedNo notable additions or deletions were detected; the page content and layout appear unchanged. The study details, eligibility criteria, and locations remain the same as in the previous view.SummaryDifference0.3%

- Check102 days agoChange DetectedThe page now explicitly notes potential delays due to funding, confirms the NIH Clinical Center is open, directs users to cc.nih.gov and opm.gov for status, and indicates a version upgrade to v3.2.0.SummaryDifference3%

Stay in the know with updates to Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.